Healthcare / Medical Care FacilitiesTaiwan
$40.00
+0.10 (+0.25%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-23.2M · quality 39.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.6B
P/E
28.8x
↑EV/EBITDA
12.3x
↓ROE
8.0%
↑Gross Margin
13.2%
↓Debt/Equity
1.05
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+20.8%
FCF CAGR
—
FCF margin
-13.6%
FCF / Net income
-1.66x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.12B · net income $91.7M · FCF $-152.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.12B | $1.12B | $982.6M | $868.7M | $636.7M |
| Net Income | $91.7M | $91.7M | $40.6M | $59.4M | $23.3M |
| EBITDA | $279.6M | $279.6M | $203.8M | $206.4M | $137.3M |
| EPS | — | — | 0.68 | 0.99 | 0.39 |
| Gross Margin | 13.2% | 13.2% | 12.6% | 13.2% | 10.3% |
| Operating Margin | 5.2% | 5.2% | 4.5% | 6.2% | 2.2% |
| Net Margin | 8.2% | 8.2% | 4.1% | 6.8% | 3.7% |
| Balance Sheet | |||||
| Debt/Equity | 1.05 | 1.05 | 1.74 | 1.41 | 1.44 |
| Current Ratio | 3.65 | 3.65 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-152.1M | $-152.1M | $111.3M | $-23.2M | $31.7M |
| Returns | |||||
| ROE | 8.0% | 8.0% | 6.3% | 9.6% | 4.2% |
| Valuation | |||||
| P/E | 28.78 | 28.78 | 140.15 | 83.46 | 88.47 |
| EV/EBITDA | 12.34 | 12.34 | 32.19 | 27.14 | 18.46 |
| P/B | 2.31 | 2.31 | 8.85 | 8.01 | 3.65 |
| Growth & Yield | |||||
| Revenue Growth | 14.2% | 14.2% | 13.1% | 36.4% | — |
| EPS Growth | — | — | -31.3% | 156.5% | — |
| Dividend Yield | 2.4% | 2.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-28.4%
Start / end P/E
n/dx → n/dx
EPS bridge
0.68 → n/d
Residual
-30.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.